Interestingly, MZF1, MZF1AS1, PARP1, and E2F1 are all associated with poor prognosis of NB patients, and blocking MZF1AS1 and PARP1 interaction, using a small peptide, or targeting MZF1AS1 suppresses Proline synthesis and tuomorigenesis, thus representing potential targets for NB therapy (42). Here, MZF1 is linked to neuroblastoma.